Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 293

1.

Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents.

Mousa SA, Ayoub BM.

Neural Regen Res. 2019 May;14(5):745-748. doi: 10.4103/1673-5374.249217. Review.

2.

Radioresistance of cancer cells, integrin αvβ3 and thyroid hormone.

Leith JT, Mousa SA, Hercbergs A, Lin HY, Davis PJ.

Oncotarget. 2018 Dec 11;9(97):37069-37075. doi: 10.18632/oncotarget.26434. eCollection 2018 Dec 11. Review.

3.

Bioactivity of Thyroid Hormone Analogs at Cancer Cells.

Davis PJ, Tang HY, Hercbergs A, Lin HY, Keating KA, Mousa SA.

Front Endocrinol (Lausanne). 2018 Dec 4;9:739. doi: 10.3389/fendo.2018.00739. eCollection 2018. Review.

4.

Activation of polymeric nanoparticle intracellular targeting overcomes chemodrug resistance in human primary patient breast cancer cells.

Abou-El-Naga AM, Mutawa G, El-Sherbiny IM, Mousa SA.

Int J Nanomedicine. 2018 Nov 29;13:8153-8164. doi: 10.2147/IJN.S182184. eCollection 2018.

5.

Thymoquinone Attenuates Cardiomyopathy in Streptozotocin-Treated Diabetic Rats.

Atta MS, El-Far AH, Farrag FA, Abdel-Daim MM, Al Jaouni SK, Mousa SA.

Oxid Med Cell Longev. 2018 Oct 30;2018:7845681. doi: 10.1155/2018/7845681. eCollection 2018.

6.

In tumor cells, thyroid hormone analogues non-immunologically regulate PD-L1 and PD-1 accumulation that is anti-apoptotic.

Lin HY, Chin YT, Shih YJ, Chen YR, Leinung M, Keating KA, Mousa SA, Davis PJ.

Oncotarget. 2018 Sep 25;9(75):34033-34037. doi: 10.18632/oncotarget.26143. eCollection 2018 Sep 25.

7.

Protective Roles of Thymoquinone Nanoformulations: Potential Nanonutraceuticals in Human Diseases.

El-Far AH, Al Jaouni SK, Li W, Mousa SA.

Nutrients. 2018 Sep 25;10(10). pii: E1369. doi: 10.3390/nu10101369. Review.

8.

Contributions of Thyroid Hormone to Cancer Metastasis.

Mousa SA, Glinsky GV, Lin HY, Ashur-Fabian O, Hercbergs A, Keating KA, Davis PJ.

Biomedicines. 2018 Aug 22;6(3). pii: E89. doi: 10.3390/biomedicines6030089. Review.

9.

Protective Effects of Miswak (Salvadora persica) against Experimentally Induced Gastric Ulcers in Rats.

Lebda MA, El-Far AH, Noreldin AE, Elewa YHA, Al Jaouni SK, Mousa SA.

Oxid Med Cell Longev. 2018 Jul 9;2018:6703296. doi: 10.1155/2018/6703296. eCollection 2018.

10.

Chitosan-based nanoformulated (-)-epigallocatechin-3-gallate (EGCG) modulates human keratinocyte-induced responses and alleviates imiquimod-induced murine psoriasiform dermatitis.

Chamcheu JC, Siddiqui IA, Adhami VM, Esnault S, Bharali DJ, Babatunde AS, Adame S, Massey RJ, Wood GS, Longley BJ, Mousa SA, Mukhtar H.

Int J Nanomedicine. 2018 Jul 20;13:4189-4206. doi: 10.2147/IJN.S165966. eCollection 2018.

11.

Tetraiodothyroacetic acid (tetrac), integrin αvβ3 and disabling of immune checkpoint defense.

Davis PJ, Mousa SA, Lin HY.

Future Med Chem. 2018 Jul 1;10(14):1637-1639. doi: 10.4155/fmc-2018-0123. Epub 2018 Jun 29. No abstract available.

12.

High Plasma Sphingosine 1-phosphate Levels Predict Osteoporotic Fractures in Postmenopausal Women: The Center of Excellence for Osteoporosis Research Study.

Ardawi MM, Rouzi AA, Al-Senani NS, Qari MH, Elsamanoudy AZ, Mousa SA.

J Bone Metab. 2018 May;25(2):87-98. doi: 10.11005/jbm.2018.25.2.87. Epub 2018 May 31.

13.

Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent.

Ayoub BM, Mowaka S, Safar MM, Ashoush N, Arafa MG, Michel HE, Tadros MM, Elmazar MM, Mousa SA.

Sci Rep. 2018 Jun 12;8(1):8959. doi: 10.1038/s41598-018-27395-0.

14.

Demonstration of the Receptor Site for Thyroid Hormone on Integrin αvβ3.

Lin HY, Mousa SA, Davis PJ.

Methods Mol Biol. 2018;1801:61-65. doi: 10.1007/978-1-4939-7902-8_7.

PMID:
29892817
15.

New Interfaces of Thyroid Hormone Actions With Blood Coagulation and Thrombosis.

Davis PJ, Mousa SA, Schechter GP.

Clin Appl Thromb Hemost. 2018 Oct;24(7):1014-1019. doi: 10.1177/1076029618774150. Epub 2018 May 9. Review.

PMID:
29742907
16.

Status and future directions in the management of pancreatic cancer: potential impact of nanotechnology.

Sielaff CM, Mousa SA.

J Cancer Res Clin Oncol. 2018 Jul;144(7):1205-1217. doi: 10.1007/s00432-018-2651-3. Epub 2018 May 2. Review.

PMID:
29721665
17.

Activation of tumor cell integrin αvβ3 by radiation and reversal of activation by chemically modified tetraiodothyroacetic acid (tetrac).

Leith JT, Hercbergs A, Kenney S, Mousa SA, Davis PJ.

Endocr Res. 2018 Nov;43(4):215-219. doi: 10.1080/07435800.2018.1456550. Epub 2018 Apr 3.

PMID:
29611723
18.

Date Palm (Phoenix dactylifera): Novel Findings and Future Directions for Food and Drug Discovery.

El-Far AH, Oyinloye BE, Sepehrimanesh M, Allah MAG, Reidah IA, Shaheen HM, Razeghian-Jahromi I, Alsenosy AEA, Noreldin AE, Al Jaouni SK, Mousa SA.

Curr Drug Discov Technol. 2018 Mar 19. doi: 10.2174/1570163815666180320111937. [Epub ahead of print]

PMID:
29557751
19.

Synthesis of new analogs of tetraiodothyroacetic acid (tetrac) as novel angiogenesis inhibitors for treatment of cancer.

Rajabi M, Yalcin M, Mousa SA.

Bioorg Med Chem Lett. 2018 Apr 15;28(7):1223-1227. doi: 10.1016/j.bmcl.2018.02.045. Epub 2018 Feb 26.

PMID:
29519736
20.

Taribavirin and 5-Fluorouracil-Loaded Pegylated-Lipid Nanoparticle Synthesis, p38 Docking, and Antiproliferative Effects on MCF-7 Breast Cancer.

Abd-Rabou AA, Bharali DJ, Mousa SA.

Pharm Res. 2018 Feb 27;35(4):76. doi: 10.1007/s11095-017-2283-3.

PMID:
29488022

Supplemental Content

Loading ...
Support Center